Suman Kundu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suman Kundu has a total of 415 co-authors. Here are the top co-authors by number of shared publications:
- A. Cecile J.W. Janssens
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
7 shared publications Matthew S. Freiberg
Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Geriatric Research Education and Clinical Centers, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA
6 shared publicationsHilary A. Tindle
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; Geriatric Research Education and Clinical Centers, Veterans Affairs Tennessee Valley Healthcare System, Nashville, Tennessee, USA
5 shared publicationsKaku A. So-Armah
Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
5 shared publications- Matthew S. Freiberg
Vanderbilt University Medical Center
5 shared publications - Aaron W. Aday
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
3 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e041096
Incidence of Right Ventricular Dysfunction in an Echocardiographic Referral Cohort
Background: Incidence rates of right ventricular dysfunction (RVD) are unknown. We examined the rates, risk factors, and heart failure (HF) hospitalization hazard associated with incident RVD and right ventricle‐pulmonary artery (RV‐PA) uncoupling in patients referred for transthoracic echocardiogram (TTE). Methods: In this retrospective cohort study, we extracted data from TTEs at Vanderbilt University Medical Cente (2010–2023). We followed patients from their earliest TTE with normal right ventricle function (tricuspid annular plane systolic excursion [TAPSE] ≥17 mm). The primary outcomes were new RVD (TAPSE 35 mm Hg associated with TAPSE declined over time. The hazard of HF hospitalization increased with incident RVD (hazard ratio, 2.02 [95% CI, 1.85–2.21]) or when TAPSE declined by ≥5 mm. Conclusions: RVD incidence is substantial among patients referred for TTE. Clinical monitoring is warranted if right ventricular systolic pressure is >35 mm Hg. Cardiovascular comorbidities drive RVD and RV‐PA uncoupling in this population. Incident RVD associates with increased HF hospitalization hazard.
- 1 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (13) , e041096
Open AccessIncidence of Right Ventricular Dysfunction in an Echocardiographic Referral Cohort
Background: Incidence rates of right ventricular dysfunction (RVD) are unknown. We examined the rates, risk factors, and heart failure (HF) hospitalization hazard associated with incident RVD and right ventricle‐pulmonary artery (RV‐PA) uncoupling in patients referred for transthoracic echocardiogram (TTE). Methods: In this retrospective cohort study, we extracted data from TTEs at Vanderbilt University Medical Cente (2010–2023). We followed patients from their earliest TTE with normal right ventricle function (tricuspid annular plane systolic excursion [TAPSE] ≥17 mm). The primary outcomes were new RVD (TAPSE 35 mm Hg associated with TAPSE declined over time. The hazard of HF hospitalization increased with incident RVD (hazard ratio, 2.02 [95% CI, 1.85–2.21]) or when TAPSE declined by ≥5 mm. Conclusions: RVD incidence is substantial among patients referred for TTE. Clinical monitoring is warranted if right ventricular systolic pressure is >35 mm Hg. Cardiovascular comorbidities drive RVD and RV‐PA uncoupling in this population. Incident RVD associates with increased HF hospitalization hazard.
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e041177
Association of Lipoprotein(a) With Major Adverse Limb Events and All‐Cause Mortality Following Revascularization for Chronic Limb‐Threatening Ischemia: A Substudy of the BEST‐CLI Trial
Background: The BEST‐CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia) trial tested the optimal initial revascularization strategy in patients with chronic limb‐threatening ischemia. Little is known about the prognostic relevance of Lp(a) (lipoprotein[a]) and its modification by renal function in patients with chronic limb‐threatening ischemia. We investigated the relationship between Lp(a) and prespecified cardiovascular outcomes. Methods: A subgroup of patients from the BEST‐CLI trial (as part of the TIDE [The Impact of Diabetes on Revascularization] study) underwent blinded, core‐laboratory assessment of Lp(a) levels and were included in this analysis. The primary end point was major adverse limb events or death from any cause. Secondary end points were the components of the primary end point, major amputation, major reintervention, and major adverse cardiac events (myocardial infarction, ischemic stroke, or death from any cause). The association of Lp(a) with end points was assessed using Cox proportional hazard models adjusting for traditional risk factors and then also for renal function and statin use, which increase Lp(a) levels. Results: A total of 189 patients (median [interquartile range] age 67.3 [61.6–74.1] years) were included and followed for a median of 2.1 (1.2–2.9) years. Median Lp(a) for the total study population was 27.3 (10.4–65.8) mg/dL, and 62 (32.8%) patients had elevated values (≥50 mg/dL). The 1‐year event rate of the primary outcome was 33.3 (95% CI, 23.7–42.8) per 100 person‐years. There was no association between Lp(a) and the primary outcome (hazard ratio [HR], 1.00 [95% CI, 0.99–1.00]; P =0.186). In secondary analyses controlling for renal function, elevated Lp(a) was associated with increased risk for all‐cause death (HR, 1.03 [95% CI, 1.01–1.05]; P =0.009). Results were similar regardless of peripheral revascularization strategy. Conclusions: Elevated Lp(a) level was not associated with major adverse limb events or death but was associated with all‐cause death after controlling for renal function. Lp(a) may be an important therapeutic target in the patient population with high‐risk chronic limb‐threatening ischemia. Registration: https://clinicaltrials.gov/study/NCT03085524 ; Unique identifier: NCT03085524.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e041177
Open AccessAssociation of Lipoprotein(a) With Major Adverse Limb Events and All‐Cause Mortality Following Revascularization for Chronic Limb‐Threatening Ischemia: A Substudy of the BEST‐CLI Trial
Background: The BEST‐CLI (Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia) trial tested the optimal initial revascularization strategy in patients with chronic limb‐threatening ischemia. Little is known about the prognostic relevance of Lp(a) (lipoprotein[a]) and its modification by renal function in patients with chronic limb‐threatening ischemia. We investigated the relationship between Lp(a) and prespecified cardiovascular outcomes. Methods: A subgroup of patients from the BEST‐CLI trial (as part of the TIDE [The Impact of Diabetes on Revascularization] study) underwent blinded, core‐laboratory assessment of Lp(a) levels and were included in this analysis. The primary end point was major adverse limb events or death from any cause. Secondary end points were the components of the primary end point, major amputation, major reintervention, and major adverse cardiac events (myocardial infarction, ischemic stroke, or death from any cause). The association of Lp(a) with end points was assessed using Cox proportional hazard models adjusting for traditional risk factors and then also for renal function and statin use, which increase Lp(a) levels. Results: A total of 189 patients (median [interquartile range] age 67.3 [61.6–74.1] years) were included and followed for a median of 2.1 (1.2–2.9) years. Median Lp(a) for the total study population was 27.3 (10.4–65.8) mg/dL, and 62 (32.8%) patients had elevated values (≥50 mg/dL). The 1‐year event rate of the primary outcome was 33.3 (95% CI, 23.7–42.8) per 100 person‐years. There was no association between Lp(a) and the primary outcome (hazard ratio [HR], 1.00 [95% CI, 0.99–1.00]; P =0.186). In secondary analyses controlling for renal function, elevated Lp(a) was associated with increased risk for all‐cause death (HR, 1.03 [95% CI, 1.01–1.05]; P =0.009). Results were similar regardless of peripheral revascularization strategy. Conclusions: Elevated Lp(a) level was not associated with major adverse limb events or death but was associated with all‐cause death after controlling for renal function. Lp(a) may be an important therapeutic target in the patient population with high‐risk chronic limb‐threatening ischemia. Registration: https://clinicaltrials.gov/study/NCT03085524 ; Unique identifier: NCT03085524.
- Open Access
Incidence of Pulmonary Hypertension in the Echocardiography Referral Population
Rationale Incidence rates for pulmonary hypertension using diagnostic data in patients with cardiopulmonary disease are not known. Objectives To determine incidence rates of, risk factors for, and mortality hazard associated with pulmonary hypertension among patients referred for transthoracic echocardiography Methods Retrospective cohort study using data from the Veterans Health Administration (1999- 2020) and Vanderbilt University Medical Center (1994-2020). Pulmonary hypertension was defined as pulmonary artery systolic pressure >35mmHg with prevalent cases excluded. Heart failure and chronic obstructive pulmonary disease were the primary exposures of interest. The primary outcome was incident pulmonary hypertension. Secondarily, we examined mortality rate following incident diagnosis. Measurements and Main Results We identified 245,067 VA patients (94% male, 20% Black) and 117,526 Vanderbilt patients (46% male, 11% Black) without pulmonary hypertension, of whom 38,882 VA patients and 8,061 Vanderbilt patients developed pulmonary hypertension. Only 18-19% of patients with echo-based pulmonary hypertension also had a diagnostic code. Hazard of pulmonary hypertension was 4-fold higher in patients with heart failure and chronic obstructive pulmonary disease compared to patients without either. Mortality rates increased from pulmonary artery systolic pressure of 35mmHg to 45mmHg then plateaued. Independent risk factors for incident pulmonary hypertension included older age, male sex, black race, and cardiometabolic comorbidities. Conclusions Pulmonary hypertension incidence rates estimated by diagnostic data are higher than code-based rates. Heart failure and chronic obstructive pulmonary disease strongly associate with incident pulmonary hypertension. Pulmonary artery systolic pressure >45mmHg at diagnosis is associated with high mortality. New pulmonary hypertension on echocardiography is an important prognostic sign.
Open AccessIncidence of Pulmonary Hypertension in the Echocardiography Referral Population
Rationale Incidence rates for pulmonary hypertension using diagnostic data in patients with cardiopulmonary disease are not known. Objectives To determine incidence rates of, risk factors for, and mortality hazard associated with pulmonary hypertension among patients referred for transthoracic echocardiography Methods Retrospective cohort study using data from the Veterans Health Administration (1999- 2020) and Vanderbilt University Medical Center (1994-2020). Pulmonary hypertension was defined as pulmonary artery systolic pressure >35mmHg with prevalent cases excluded. Heart failure and chronic obstructive pulmonary disease were the primary exposures of interest. The primary outcome was incident pulmonary hypertension. Secondarily, we examined mortality rate following incident diagnosis. Measurements and Main Results We identified 245,067 VA patients (94% male, 20% Black) and 117,526 Vanderbilt patients (46% male, 11% Black) without pulmonary hypertension, of whom 38,882 VA patients and 8,061 Vanderbilt patients developed pulmonary hypertension. Only 18-19% of patients with echo-based pulmonary hypertension also had a diagnostic code. Hazard of pulmonary hypertension was 4-fold higher in patients with heart failure and chronic obstructive pulmonary disease compared to patients without either. Mortality rates increased from pulmonary artery systolic pressure of 35mmHg to 45mmHg then plateaued. Independent risk factors for incident pulmonary hypertension included older age, male sex, black race, and cardiometabolic comorbidities. Conclusions Pulmonary hypertension incidence rates estimated by diagnostic data are higher than code-based rates. Heart failure and chronic obstructive pulmonary disease strongly associate with incident pulmonary hypertension. Pulmonary artery systolic pressure >45mmHg at diagnosis is associated with high mortality. New pulmonary hypertension on echocardiography is an important prognostic sign.
- 27 November 2023
- Published by Elsevier in The Journal of Pain
- Vol. 25 (5) , 104436
The Association of Prescribed Opioids and Incident Cardiovascular Disease
- 27 November 2023
- Published by Elsevier in The Journal of Pain
- Vol. 25 (5) , 104436
The Association of Prescribed Opioids and Incident Cardiovascular Disease
- 11 July 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 135-143
Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans
Background: People with HIV (PWH) have an increased risk of cardiovascular disease. Previous cross-sectional data suggest there is a higher prevalence of abdominal aortic aneurysm (AAA) in PWH than in those without HIV. Whether PWH have an increased risk of incident AAA compared with those without HIV is unknown. Methods: We analyzed data among participants without prevalent AAA from the Veterans Aging Cohort Study, a prospective, observational, longitudinal cohort of veterans with HIV matched 1:2 with veterans without HIV infection. We calculated AAA rates by HIV status and assessed the association between HIV infection and incident AAA using Cox proportional hazards models. We defined AAA using the International Classification of Diseases, 9th or 10th revision, or Current Procedural Terminology codes and adjusted all models for demographic characteristics, cardiovascular disease risk factors, and substance use. Secondary analyses examined the association between time-varying CD4+ T-cell count or HIV viral load and incident AAA. Results: Among 143 001 participants (43 766 with HIV), over a median follow-up of 8.7 years, there were 2431 incident AAA events (26.4% among PWH). Rates of incident AAA per 1000 person-years were similar among PWH (2.0 [95% CI, 1.9–2.2]) and people without HIV (2.2 [95% CI, 2.1–2.3]). There was no evidence that HIV infection increased the risk of incident AAA compared with no HIV infection (adjusted hazard ratio, 1.02 [95% CI, 0.92–1.13]). In adjusted analyses with time-varying CD4+ T-cell counts or HIV viral load, PWH with CD4+ T-cell counts 3 (adjusted hazard ratio, 1.29 [95% CI, 1.02–1.65]) or HIV viral load ≥500 copies/mL (adjusted hazard ratio, 1.29 [95% CI, 1.09–1.52]) had an increased risk of AAA compared with those without HIV. Conclusions: HIV infection is associated with an increased risk of AAA among those with low CD4+ T-cell counts or elevated HIV viral load over time.
- 11 July 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 148 (2) , 135-143
Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans
Background: People with HIV (PWH) have an increased risk of cardiovascular disease. Previous cross-sectional data suggest there is a higher prevalence of abdominal aortic aneurysm (AAA) in PWH than in those without HIV. Whether PWH have an increased risk of incident AAA compared with those without HIV is unknown. Methods: We analyzed data among participants without prevalent AAA from the Veterans Aging Cohort Study, a prospective, observational, longitudinal cohort of veterans with HIV matched 1:2 with veterans without HIV infection. We calculated AAA rates by HIV status and assessed the association between HIV infection and incident AAA using Cox proportional hazards models. We defined AAA using the International Classification of Diseases, 9th or 10th revision, or Current Procedural Terminology codes and adjusted all models for demographic characteristics, cardiovascular disease risk factors, and substance use. Secondary analyses examined the association between time-varying CD4+ T-cell count or HIV viral load and incident AAA. Results: Among 143 001 participants (43 766 with HIV), over a median follow-up of 8.7 years, there were 2431 incident AAA events (26.4% among PWH). Rates of incident AAA per 1000 person-years were similar among PWH (2.0 [95% CI, 1.9–2.2]) and people without HIV (2.2 [95% CI, 2.1–2.3]). There was no evidence that HIV infection increased the risk of incident AAA compared with no HIV infection (adjusted hazard ratio, 1.02 [95% CI, 0.92–1.13]). In adjusted analyses with time-varying CD4+ T-cell counts or HIV viral load, PWH with CD4+ T-cell counts 3 (adjusted hazard ratio, 1.29 [95% CI, 1.02–1.65]) or HIV viral load ≥500 copies/mL (adjusted hazard ratio, 1.29 [95% CI, 1.09–1.52]) had an increased risk of AAA compared with those without HIV. Conclusions: HIV infection is associated with an increased risk of AAA among those with low CD4+ T-cell counts or elevated HIV viral load over time.
- 1 September 2022
- Published by American Psychological Association (APA) in Health Psychology
- Vol. 41 (9) , 621-629
Dispositional optimism and optimistic bias: Associations with cessation motivation, confidence, and attitudes.
To test whether 2 conceptually overlapping constructs, dispositional optimism (generalized positive expectations) and optimistic bias (inaccurately low risk perceptions), may have different implications for smoking treatment engagement. Predominantly Black, low-income Southern Community Cohort study smokers (n = 880) self-reported dispositional optimism and pessimism (Life Orientation Test-Revised subscales: 0 = neutral, 12 = high optimism/pessimism), comparative lung cancer risk (Low/Average/High), and information to calculate objective lung cancer risk (Low/Med/High). Perceived risk was categorized as accurate (perceived = objective), optimistically-biased (perceived < objective), or pessimistically-biased (perceived > objective). One-way ANOVAs tested associations between dispositional optimism/pessimism and perceived risk accuracy. Multivariable logistic regressions tested independent associations of optimism/pessimism and perceived risk accuracy with cessation motivation (Low/High), confidence (Low/High), and precision treatment attitudes (Favorable/Unfavorable), controlling for sociodemographics and nicotine dependence. Mean dispositional optimism/pessimism scores were 8.41 (SD = 2.59) and 5.65 (SD = 3.02), respectively. Perceived lung cancer risk was 38% accurate, 27% optimistically-biased, and 35% pessimistically-biased. Accuracy was unrelated to dispositional optimism (F(2, 641) = 1.23, p = .29), though optimistically-biased (vs. pessimistically-biased) smokers had higher dispositional pessimism (F(2, 628) = 3.17, p = .043). Dispositional optimism was associated with higher confidence (Adjusted odds ratio [AOR] = 1.71, 95% CI [1.42, 2.06], p < .001) and favorable precision treatment attitudes (AOR = 1.66, 95% CI [1.37, 2.01], p < .001). Optimistically-biased (vs. accurate) risk perception was associated with lower motivation (AOR = .64, 95% CI [.42, .98], p = .041) and less favorable precision treatment attitudes (AOR = .59, 95% CI [.38, .94], p = .029). Dispositional optimism and lung cancer risk perception accuracy were unrelated. Dispositional optimism was associated with favorable engagement-related outcomes and optimistically-biased risk perception with unfavorable outcomes, reinforcing the distinctiveness of these constructs and their implications for smoking treatment. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- 1 September 2022
- Published by American Psychological Association (APA) in Health Psychology
- Vol. 41 (9) , 621-629
Dispositional optimism and optimistic bias: Associations with cessation motivation, confidence, and attitudes.
To test whether 2 conceptually overlapping constructs, dispositional optimism (generalized positive expectations) and optimistic bias (inaccurately low risk perceptions), may have different implications for smoking treatment engagement. Predominantly Black, low-income Southern Community Cohort study smokers (n = 880) self-reported dispositional optimism and pessimism (Life Orientation Test-Revised subscales: 0 = neutral, 12 = high optimism/pessimism), comparative lung cancer risk (Low/Average/High), and information to calculate objective lung cancer risk (Low/Med/High). Perceived risk was categorized as accurate (perceived = objective), optimistically-biased (perceived < objective), or pessimistically-biased (perceived > objective). One-way ANOVAs tested associations between dispositional optimism/pessimism and perceived risk accuracy. Multivariable logistic regressions tested independent associations of optimism/pessimism and perceived risk accuracy with cessation motivation (Low/High), confidence (Low/High), and precision treatment attitudes (Favorable/Unfavorable), controlling for sociodemographics and nicotine dependence. Mean dispositional optimism/pessimism scores were 8.41 (SD = 2.59) and 5.65 (SD = 3.02), respectively. Perceived lung cancer risk was 38% accurate, 27% optimistically-biased, and 35% pessimistically-biased. Accuracy was unrelated to dispositional optimism (F(2, 641) = 1.23, p = .29), though optimistically-biased (vs. pessimistically-biased) smokers had higher dispositional pessimism (F(2, 628) = 3.17, p = .043). Dispositional optimism was associated with higher confidence (Adjusted odds ratio [AOR] = 1.71, 95% CI [1.42, 2.06], p < .001) and favorable precision treatment attitudes (AOR = 1.66, 95% CI [1.37, 2.01], p < .001). Optimistically-biased (vs. accurate) risk perception was associated with lower motivation (AOR = .64, 95% CI [.42, .98], p = .041) and less favorable precision treatment attitudes (AOR = .59, 95% CI [.38, .94], p = .029). Dispositional optimism and lung cancer risk perception accuracy were unrelated. Dispositional optimism was associated with favorable engagement-related outcomes and optimistically-biased risk perception with unfavorable outcomes, reinforcing the distinctiveness of these constructs and their implications for smoking treatment. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
- Open Access
- 21 September 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (18) , e021268
HIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death
Background: People living with HIV have higher sudden cardiac death (SCD) rates compared with the general population. Whether HIV infection is an independent SCD risk factor is unclear. Methods and Results: This study evaluated participants from the Veterans Aging Cohort Study, an observational, longitudinal cohort of veterans with and without HIV infection matched 1:2 on age, sex, race/ethnicity, and clinical site. Baseline for this study was a participant's first clinical visit on or after April 1, 2003. Participants were followed through December 31, 2014. Using Cox proportional hazards regression, we assessed whether HIV infection, CD4 cell counts, and/or HIV viral load were associated with World Health Organization (WHO)–defined SCD risk. Among 144 336 participants (30% people living with HIV), the mean (SD) baseline age was 50.0 years (10.6 years), 97% were men, and 47% were of Black race. During follow‐up (median, 9.0 years), 3035 SCDs occurred. HIV infection was associated with increased SCD risk (hazard ratio [HR], 1.14; 95% CI, 1.04–1.25), adjusting for possible confounders. In analyses with time‐varying CD4 and HIV viral load, people living with HIV with CD4 counts 500 copies/mL (HR, 1.70; 95% CI, 1.46–1.98) had increased SCD risk versus veterans without HIV. In contrast, people living with HIV who had CD4 cell counts >500 cells/mm 3 (HR, 1.03; 95% CI, 0.90–1.18) or HIV viral load <500 copies/mL (HR, 0.97; 95% CI, 0.87–1.09) were not at increased SCD risk. Conclusions: HIV infection is associated with increased risk of WHO‐defined SCD among those with elevated HIV viral load or low CD4 cell counts.
- 21 September 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (18) , e021268
Open AccessHIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death
Background: People living with HIV have higher sudden cardiac death (SCD) rates compared with the general population. Whether HIV infection is an independent SCD risk factor is unclear. Methods and Results: This study evaluated participants from the Veterans Aging Cohort Study, an observational, longitudinal cohort of veterans with and without HIV infection matched 1:2 on age, sex, race/ethnicity, and clinical site. Baseline for this study was a participant's first clinical visit on or after April 1, 2003. Participants were followed through December 31, 2014. Using Cox proportional hazards regression, we assessed whether HIV infection, CD4 cell counts, and/or HIV viral load were associated with World Health Organization (WHO)–defined SCD risk. Among 144 336 participants (30% people living with HIV), the mean (SD) baseline age was 50.0 years (10.6 years), 97% were men, and 47% were of Black race. During follow‐up (median, 9.0 years), 3035 SCDs occurred. HIV infection was associated with increased SCD risk (hazard ratio [HR], 1.14; 95% CI, 1.04–1.25), adjusting for possible confounders. In analyses with time‐varying CD4 and HIV viral load, people living with HIV with CD4 counts 500 copies/mL (HR, 1.70; 95% CI, 1.46–1.98) had increased SCD risk versus veterans without HIV. In contrast, people living with HIV who had CD4 cell counts >500 cells/mm 3 (HR, 1.03; 95% CI, 0.90–1.18) or HIV viral load <500 copies/mL (HR, 0.97; 95% CI, 0.87–1.09) were not at increased SCD risk. Conclusions: HIV infection is associated with increased risk of WHO‐defined SCD among those with elevated HIV viral load or low CD4 cell counts.
- Open Access
- 6 July 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (13) , e017637
Depression as a Risk Factor for Incident Ischemic Stroke Among HIV‐Positive Veterans in the Veterans Aging Cohort Study
Background: HIV infection and depression are each associated with increased ischemic stroke risk. Whether depression is a risk factor for stroke within the HIV population is unknown. Methods and Results: We analyzed data on 106 333 (33 528 HIV‐positive; 72 805 HIV‐negative) people who were free of baseline cardiovascular disease from an observational cohort of HIV‐positive people and matched uninfected veterans in care from April 1, 2003 through December 31, 2014. International Classification of Diseases, Ninth Revision ( ICD‐9 ) codes from medical records were used to determine baseline depression and incident stroke. Depression occurred in 19.5% of HIV‐positive people. After a median of 9.2 years of follow‐up, stroke rates were highest among people with both HIV and depression and lowest among those with neither condition. In Cox proportional hazard models, depression was associated with an increased risk of stroke for HIV‐positive people after adjusting for sociodemographic characteristics and cerebrovascular risk factors (hazard ratio [HR], 1.18; 95% CI: 1.03–1.34; 0.014). The depression‐stroke relationship was attenuated by alcohol use disorders, cocaine use, and baseline antidepressant use, and unaffected by combined antiretroviral therapy use or individual antiretroviral agents. A numerically higher HR of depression on stroke was found among those younger than 60 years. Conclusions: Depression is associated with an increased risk of stroke among HIV‐positive people after adjusting for sociodemographic characteristics, traditional cerebrovascular risk factors, and HIV‐specific factors. Alcohol use disorders, cocaine use, and baseline antidepressant use accounted for some of the observed stroke risk. Depression may be a novel, independent risk factor for ischemic stroke in HIV, particularly among younger people.
- 6 July 2021
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (13) , e017637
Open AccessDepression as a Risk Factor for Incident Ischemic Stroke Among HIV‐Positive Veterans in the Veterans Aging Cohort Study
Background: HIV infection and depression are each associated with increased ischemic stroke risk. Whether depression is a risk factor for stroke within the HIV population is unknown. Methods and Results: We analyzed data on 106 333 (33 528 HIV‐positive; 72 805 HIV‐negative) people who were free of baseline cardiovascular disease from an observational cohort of HIV‐positive people and matched uninfected veterans in care from April 1, 2003 through December 31, 2014. International Classification of Diseases, Ninth Revision ( ICD‐9 ) codes from medical records were used to determine baseline depression and incident stroke. Depression occurred in 19.5% of HIV‐positive people. After a median of 9.2 years of follow‐up, stroke rates were highest among people with both HIV and depression and lowest among those with neither condition. In Cox proportional hazard models, depression was associated with an increased risk of stroke for HIV‐positive people after adjusting for sociodemographic characteristics and cerebrovascular risk factors (hazard ratio [HR], 1.18; 95% CI: 1.03–1.34; 0.014). The depression‐stroke relationship was attenuated by alcohol use disorders, cocaine use, and baseline antidepressant use, and unaffected by combined antiretroviral therapy use or individual antiretroviral agents. A numerically higher HR of depression on stroke was found among those younger than 60 years. Conclusions: Depression is associated with an increased risk of stroke among HIV‐positive people after adjusting for sociodemographic characteristics, traditional cerebrovascular risk factors, and HIV‐specific factors. Alcohol use disorders, cocaine use, and baseline antidepressant use accounted for some of the observed stroke risk. Depression may be a novel, independent risk factor for ischemic stroke in HIV, particularly among younger people.